MXPA02005069A - Agentes de enlace especificos para t3 y metodos para su uso. - Google Patents

Agentes de enlace especificos para t3 y metodos para su uso.

Info

Publication number
MXPA02005069A
MXPA02005069A MXPA02005069A MXPA02005069A MXPA02005069A MX PA02005069 A MXPA02005069 A MX PA02005069A MX PA02005069 A MXPA02005069 A MX PA02005069A MX PA02005069 A MXPA02005069 A MX PA02005069A MX PA02005069 A MXPA02005069 A MX PA02005069A
Authority
MX
Mexico
Prior art keywords
specific binding
binding agents
methods
biologically active
agents
Prior art date
Application number
MXPA02005069A
Other languages
English (en)
Inventor
Thomas V Tittle
Original Assignee
Wegmann Keith W
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wegmann Keith W filed Critical Wegmann Keith W
Publication of MXPA02005069A publication Critical patent/MXPA02005069A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
MXPA02005069A 1999-11-19 2000-11-17 Agentes de enlace especificos para t3 y metodos para su uso. MXPA02005069A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16658399P 1999-11-19 1999-11-19
PCT/US2000/031692 WO2001035995A2 (en) 1999-11-19 2000-11-17 Tr3-specific binding agents and methods for their use

Publications (1)

Publication Number Publication Date
MXPA02005069A true MXPA02005069A (es) 2003-09-25

Family

ID=22603921

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02005069A MXPA02005069A (es) 1999-11-19 2000-11-17 Agentes de enlace especificos para t3 y metodos para su uso.

Country Status (7)

Country Link
US (1) US20050282223A1 (es)
EP (1) EP1231937A2 (es)
JP (1) JP2003514031A (es)
AU (2) AU784504B2 (es)
CA (1) CA2391530A1 (es)
MX (1) MXPA02005069A (es)
WO (1) WO2001035995A2 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003013581A1 (en) * 2001-08-03 2003-02-20 Genset S.A. Agonists and antagonists of genceptin for the treatment of metabolic disorders
EP1667730B1 (en) * 2003-08-20 2013-06-26 University of Miami Compositions and methods for treating inflammatory lung disease
GB0413688D0 (en) * 2004-06-18 2004-07-21 Novartis Forschungsstiftung Analysis of methylated nucleic acid
CA2621083C (en) 2005-08-30 2017-04-11 University Of Miami Immunomodulating tumor necrosis factor receptor 25 (tnfr25) agonists, antagonists and immunotoxins
US20110195048A1 (en) * 2008-10-08 2011-08-11 Podack Eckhard R Regulation of lymphocytes and uses therefor
KR20120089259A (ko) * 2009-08-03 2012-08-09 유니버시티 오브 마이애미 Ｔ 조절 세포의 생체 내 확장 방법
MX2013009859A (es) 2011-03-01 2014-02-28 Novo Nordisk As Ligandos dr3 antagonicos.
US9127081B2 (en) 2012-05-10 2015-09-08 Washington University Tumor targeted TNF-related apoptosis inducing ligand fusion polypeptide and nucleic acids encoding the same
KR102565827B1 (ko) 2013-01-09 2023-08-11 유니버시티 오브 마이애미 TL1A-Ig 융합 단백질을 사용한 T 조절 세포의 조절을 위한 조성물 및 방법
WO2015152430A1 (en) * 2014-04-04 2015-10-08 Kyowa Hakko Kirin Co., Ltd. Anti-death receptor 3 (dr3) antagonistic antibodies with reduced agonistic activity

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997033904A1 (en) * 1996-03-12 1997-09-18 Human Genome Sciences, Inc. Death domain containing receptors
JP2000507829A (ja) * 1996-04-01 2000-06-27 ジェネンテック インコーポレーテッド Ａｐｏ―２ｌｉおよびａｐｏ―３アポトーシスポリペプチド
CN101024831A (zh) * 1996-08-07 2007-08-29 拜奥根Idec马萨诸塞公司 肿瘤坏死因子相关配基
US6462176B1 (en) * 1996-09-23 2002-10-08 Genentech, Inc. Apo-3 polypeptide
WO1999019490A1 (en) * 1997-10-10 1999-04-22 Genentech, Inc. Apo-3 ligand
JP2003522118A (ja) * 1999-04-22 2003-07-22 ヒューマン・ジェノム・サイエンシズ・インコーポレイテッド デスドメイン含有受容体

Also Published As

Publication number Publication date
JP2003514031A (ja) 2003-04-15
AU1776201A (en) 2001-05-30
EP1231937A2 (en) 2002-08-21
WO2001035995A3 (en) 2001-11-22
CA2391530A1 (en) 2001-05-25
US20050282223A1 (en) 2005-12-22
WO2001035995A2 (en) 2001-05-25
AU784504B2 (en) 2006-04-13
AU2006202940A1 (en) 2006-08-03

Similar Documents

Publication Publication Date Title
JO2373B1 (en) W-carboxy-aryl diphenyl urease substitutes used as RAV inhibitors
DE10085007T1 (de) Antiinfektionszusammensetzungen zur Behandlung von erkranktem Gewebe, wie Lippenherpes
IL197686A0 (en) Pharmaceutical compositions containing alpha-4 integrin antagonists and uses thereof in the treatment of multiple myeloma and diseases associated therewith
TR200102648T2 (tr) Büyümeyi destekleyen bileşimler
EA200200990A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы дельта человека
BG101284A (en) Compounds and methods for cancer treatment
WO2004009767A3 (en) Cell therapy for regeneration
BRPI0415752A (pt) métodos, composições e dispositivos para indução de estase em células, tecidos, órgãos e organismos
WO2001043732A3 (en) Use of retinoid receptor antagonists in the treatment of cartilage and bone pathologies
EP1178988A4 (en) THERAPEUTIC COMPOUNDS AND METHODS
SI1546088T1 (sl) Spojine za uporabo v zdravljenju avtoimunskih bolezni, imunoalergijskih bolezni in zavrnitve transpalantata organa ali tkiva
MXPA02005069A (es) Agentes de enlace especificos para t3 y metodos para su uso.
ATE368455T1 (de) Verwendung von (+)-tramadol, o-demethyltramadol, o-desmethyl-n-mono-desmethyl-tramadol zur therapie der harninkontinenz
DE60120162D1 (en) Polyamin-analoge als cytotoxische wirkstoffe
DE60140960D1 (de) Verwendung von serp-1 in kombination mit einem immunosuppressor zur behandlung von arthritis
ATE359798T1 (de) Verwendungvon dextransulfat zur behandlung von ibmir
WO2003102162A3 (en) Novel tolerogenic dendritic cells and therapeutic uses therefor
MXPA00010254A (es) Tratamiento de disfuncion sexual en ciertos grupos de pacientes.
WO2001094586A3 (en) Non-agonistic antibodies to human gp39, compositions containing, and therapeutic use thereof
TR200200278T2 (tr) Kalsilitik bileşimler
WO2001074296A3 (en) Treatment of non-solid mammalian tumors with vascular endothelial growth factor receptor antagonists
HUP0300923A2 (hu) RAF és RAS protein kinázt tartalmazó készítmények és alkalmazásuk angiogenezis módosítására
AU7944700A (en) Bio-artificial substrate for the production of animal and, in particular, human tissues and organs
SI1596879T1 (sl) Uporaba spojine kahalalida za pripravo zdravila za zdravljenje luskavice
NO20016380L (no) Fremgangsmåte for å forhindre tumorvekst

Legal Events

Date Code Title Description
FA Abandonment or withdrawal